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Abstract
Background: Artesunate-amodiaquine combination for the treatment of childhood malaria is one
of the artemisinin combination therapies (ACTs) recommended by National authorities in many
African countries today. Effectiveness data on this combination in young children is scarce.
Methods: The effectiveness of three daily doses of artesunate plus amodiaquine combination given
unsupervised (n = 32), compared with the efficacy when given under full supervision (n = 29) to
children with falciparum malaria were assessed in an unrandomized study.
Results: 61 patients analysed revealed a PCR-corrected day-28 cure rate of 86 % (25 of 29
patients; CI 69 – 95 %) in the supervised group and 63 % (20 of 32 patients; CI 45 – 77 %) in the
unsupervised group. The difference in outcome between both groups was statistically significant (p
= 0.04). No severe adverse events were reported.
Conclusion: The effectiveness of this short course regimen in young children with falciparum
malaria could be augmented by increased adherence and improved formulation.
Background
Antimalarial chemotherapy has been the primary option
in the fight against malaria. However, the burden of this
disease is still very heavy partly due to the development of
multi-drug resistant Plasmodium falciparum strains [1-4].
The malaria community presently considers mono-ther-
apy as an inappropriate approach for malaria treat-
ment[5]. African countries have recently begun to scale up
their antimalarial efforts, and are deploying strategies to
combat the new face of malaria. One of these strategies is
the use of artemisinin-based combination therapies
(ACTs) which have proven to be very effective against
malaria in Africa, and some African countries plagued
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with resistant forms of P.falciparum have started institut-
ing the ACTs as first line malaria treatment [6,7].
Artesunate plus amodiaquine combination is one ACT
recommended by the World Health Organization (WHO)
for use in malaria control programmes and a first line
treatment for African children with uncomplicated
malaria [8]. This recommendation is now a national pol-
icy in Gabon.
Artesunate and amodiaquine are generally safe and well
tolerated when used as treatment for malaria [9-18]. In a
previous study the efficacy of artesunate-amodiaquine for
uncomplicated P. falciparum malaria in Gabonese chil-
dren was 94% [19], but the effectiveness of this combina-
tion under outpatient conditions in Gabon is not known.
There have been very few effectiveness studies on ACTs.
Depoortere et al. [20] found that patients who received a
combination of sulphadoxine/pyrimethamine and artesu-
nate under supervision achieved a 28-day PCR corrected
cure rate of 84% and effectiveness rate of 63%. The critical
reader of the paper by Piola and colleagues [21] will find
that despite final cure rates of 98% and 97% in both
supervised and unsupervised subjects, there were substan-
tial differences in lumefantrine blood concentrations in
patients from the two groups, indicating that sometimes a
difference between the efficacy and effectiveness of a
highly efficacious drug like artemether-lumefantrine may
not be demonstrable. It is important, therefore, that effec-
tiveness of drugs is measured alongside clinical efficacy,
considering that under everyday conditions many drug
combinations do not reach the same cure rates that were
measured in clinical trials under ideal conditions and
supervised drug intake.
In the present study, we assessed the effectiveness of three-
day artesunate plus amodiaquine combination adminis-
tered unsupervised, compared with the efficacy when
given under supervision to children with P. falciparum
malaria was assessed.
Methods
Study site
This study was conducted a study in Lambaréné from July
2004 to June 2005 on a cohort of children participating in
an ongoing trial at the Medical Research Unit of the Albert
Schweitzer Hospital (HAS), Gabon. Lambaréné is a small
town of approximately 30,000 inhabitants located near
the equator in the Central African rainforest belt. Malaria
transmission is moderate and perennial. 95% of all
malaria infections are caused by P. falciparum and the
entomological inoculation rate is about 50 infective bites
per person per year [22,23].
Study population
The study subjects are a subgroup of participants in a pro-
spective Intermittent Preventive Treatment intervention
(IPTi) trial [24,25] – administering treatment doses of sul-
phadoxine – pyrimethamine (or placebo) to children at
three, nine and 15 months and following them up
monthly for 30 months.
All participants of the IPTi trial were included who had
uncomplicated malaria, defined as the presence of asexual
parasitaemia of P. falciparum with a rectal temperature of
at least 38.5 °C or a history of fever in the last 48 hours.
Written or documented oral consent of the parents or the
guardians of the children were obtained at enrolment into
the main study, usually after birth in the maternity ward
of the Albert Schweitzer Hospital or the Public Regional
Hospital in Lambaréné. Ethical clearance was obtained
from the Ethics Committee of the International Founda-
tion of the Albert Schweitzer Hospital in Lambaréné.
Two groups of children were compared; those that
received artesunate plus amodiaquine combination under
supervision and those who received the combination
unsupervised. Assignment of the two groups was not ran-
domized. According to the IPTi protocol, all study sub-
jects with falciparum malaria were treated with three daily
doses of artesunate plus amodiaquine combination from
July 2004. The first dose was administered at the Medical
Research Unit and the second and third doses at home.
This treatment was classified as unsupervised. Then, from
December 2004 all patients received all three doses of
artesunate-amodiaquine combination under supervision
at the Medical Research Unit. This treatment was classified
as supervised.
All cases that had (i) a mixed infection or (ii) received a
sufficient dose of another antimalarial drug a week prior
or during the 28-day post-malaria follow-up period or
(iii) taken the IPTi study medication a week prior or dur-
ing the 28-day post-malaria follow-up period were
excluded from intention to treat (ITT) analysis. If they
vomited the artesunate plus amodiaquine combination
twice, they were excluded from the evaluability analysis.
Study procedure
Treatment consisted of a daily oral dose of artesunate 4
mg/kg body weight plus amodiaquine 10 mg/kg body
weight given for three days (ARSUCAM™ provided by
Sanofi Synthélabo). Artesunate and amodiaquine were
supplied in tablets which were crushed then mixed with
sugar into syrup and given orally. A full dose of artesu-
nate-amodiaquine combination was re-administered after
30 minutes if the child either spat the medication out or
vomited within one hour.Malaria Journal 2007, 6:29 http://www.malariajournal.com/content/6/1/29
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The day of treatment was considered as day 0. Patients
were invited for follow up visits on days 2 and 28. A clin-
ical and laboratory assessment was done on these follow
up visits. These included a thick blood smear and a full
blood count. The Giemsa-stained thick smears which
were read by at least two experienced microscopists. Para-
sitaemia was quantified (number/μL) by the Lambaréné
method [26]. A smear was declared negative only after
≥100 visual fields were scrutinized.
We advised the parent or guardian to administer doses as
seen or practiced with the first dose, and to report back to
the hospital if the child vomited or refused to take the
medication. We also encouraged the parents or guardians
to return back to the hospital at any time in case the
child's health appeared to deteriorate.
Definition of study end points
Our primary outcome was defined as a parasitological
cure on day 28. Failure was defined as persistent parasitae-
mia or reappearance of parasites during the follow-up
period of 28 days. Our secondary outcome was the safety
of the artesunate-amodiaquine combination drug meas-
ured as the frequency of adverse events. These were
defined as any signs or symptoms or any abnormal labo-
ratory value not present on day 0 or becoming worse dur-
ing follow up and were judged by the clinicians in the
study with respect to severity and relationship to study
drug.
Full blood count
We measured the haemoglobin (Hb), white blood cell
count (WBC) and neutrophils count on days 0 and 28
with an automated analyser (Cell-Dyn 3000™, Abbott
Diagnostics Santa Clara, CA).
MSA-1 and MSA-2 genotyping
Filter-paper blots (Glass fibre filters: Schleicher & Schuell
MicroScience, Dassel, Germany) were taken on day 0 and
on the day of recurrent parasitaemia for polymerase chain
reaction (PCR). For optimal differentiation between
strains, and as described before [27,28], we genotyped
parasites for merozoite surface antigens MSA-1 and MSA-
2 as two non-linked genotypical markers, in order to dis-
tinguish between re-infection and recrudescence in the
case of reappearance of parasites during the follow-up
period of 28 days.
Data analysis
Efficacy was assessed by evaluability (according-to-proto-
col, ATP) and ITT (intention-to-treat) analysis. Cure rates
were calculated from the number of patients with clinical
and parasitological cure by day 28 divided by total
number of patients in the ITT population or per protocol
population respectively. The according-to-protocol popu-
lation was defined as children who completed the 3-day
regimen of daily artesunate plus amodiaquine and had a
day 28-follow up visit (+/- 1 week). There were 61 cases
eligible for ATP analysis. The intention-to-treat popula-
tion was defined as children who took at least the first
dose. There were 89 cases eligible for ITT analysis. Based
on a previous randomized trial of artesunate plus amodi-
aquine in our study area [18], a PCR-corrected day-28 cure
rate of 90 % in the observed group was assumed.
Any data inconsistencies were reconciled, and the data
were analyzed with the statistical software JMP 5.0 and
Stata 8.2 (StataCorp, Texas, USA). A descriptive analysis of
both observed and unobserved group was made, and con-
tinuous data (age, temperature and haemoglobin concen-
trations) between groups by unpaired t-test and
categorical variables with a chi-square test were compared.
Results
Figure 1 depicts the trial profile. Baseline characteristics of
study subjects are given in table 1. In the ATP analysis of
this cohort of 61 patients, the proportion of children
cured in the supervised group was 86% (25/29, 95% CI;
69% – 95%) and 63% (20/32, 95% CI; 45% – 77%) in the
unsupervised group (p = 0.04) (Table 2). Intention-to-
treat analysis yielded a similar decrease in proportion
cured; 63% (30/48, 95 % CI; 48 – 75%) in the supervised
group and 49% (20/41, 95 % CI; 34% – 63%) in the unsu-
pervised group (p = 0.2).
The risk ratio in the ATP analysis indicates that supervised
administration of artesunate plus amodiaquine combina-
tion to children aged below 30 months have a lower risk
of failure to treatment compared to when unsupervised
(risk ratio= 0.38, p = 0.04). Supervised administration of
artesunate plus amodiaquine combination to children
aged below 30 months is also positively associated with
an increase in probability of achieving a cure from
uncomplicated malaria (risk ratio of 1.4 and 1.2 respec-
tively in the ATP and ITT analysis). This translates into an
increase of 27% benefit if administration of this drug is
supervised. Equivalently, one more cure with artesunate
plus amodiaquine can be achieved for every 4 patients
treated under supervision.
The median parasitaemia of our cohort was 7,500 para-
sites/μL. The mean haemoglobin concentration in the
supervised and unsupervised groups on day 0 were 8.7 g/
dL and 8.1 g/dL respectively (p = 0.16), and on day 28
were 9.5 g/dL and 8.9 g/dL respectively (p = 0.03). The
mean changes were not different between the groups.
However, on day 0, thirty-nine patients (64%) had ane-
mia defined as haemoglobin between 5 and 9 g/dL. On
day 28, eighteen patients (30%) fell under this definitionMalaria Journal 2007, 6:29 http://www.malariajournal.com/content/6/1/29
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Trial profile Figure 1
Trial profile.
Cohort of 100 malaria cases followed up
89 cases eligible [ITT population]
ATP population
32 children: unsupervised 29 children: supervised
PCR-corrected cure rate: unsupervised
63% (95 % CI, 45% – 77%)
4 mixed infections
4 on IPTI study rug d
3 hx of vomiting
7 protocol violations
12 lost to follow-up
2 protocol violations
7 lost to follow-up
PCR-corrected cure rate: supervised
86% (95 % CI, 69% – 95%)
48 children: supervised 41 children: unsupervised
ATP AnalysisMalaria Journal 2007, 6:29 http://www.malariajournal.com/content/6/1/29
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of anemia. Overall the mean haemoglobin concentration
increased from 8.4 g/dL on day 0 to 9.2 g/dL by day 28.
There were 36 adverse events reported during the course
of this study, the most reported were cough (18%), diar-
rhoea (12%), vomiting (5.6%), and skin infections
(4.5%). There was no serious adverse event or death
recorded. In the supervised group, two subjects were
treated with the five-day artesunate monotherapy [29],
because they vomited after a repeated dose of artesunate
plus amodiaquine. Three subjects missed the second dose,
one missed the third dose and 1 missed the second and
third dose, while in the unsupervised group, two subjects
were hospitalized for weakness. These nine protocol vio-
lations were excluded from the ATP analysis.
Discussion
This study shows that supervised administration of artesu-
nate plus amodiaquine to Gabonese children aged less
than 30 months with uncomplicated falciparum malaria
substantially reduces the risk of treatment failure com-
pared to unsupervised administration. The proportion of
supervised children cured by day 28 was 86%, while that
of unsupervised children was substantially lower (63%).
In a previous randomized study carried out in Lambaréné,
supervised administration of artesunate plus amodi-
aquine achieved a PCR corrected cure rate of 94% by day
28 [19]. The difference in proportion cured when super-
vised and when unsupervised does not only reflect the sig-
nificant gap between the usual optimistic efficacy reports
of studies and the real-life situation [20], but puts ques-
tion on the effectiveness of this combination in the treat-
ment of young children with falciparum malaria
especially under the usual unsupervised outpatient condi-
tion.
Artesunate plus amodiaquine combination was well toler-
ated. There were no serious adverse events reported during
the course of this study. The weakness of our study was
that it was not randomized and the sample size was rela-
tively small. Crushed tablets that are probably harder to
administer than palatable syrup were used. There is a clear
benefit of supervised compared to an unsupervised treat-
ment shown in the ATP analysis which was less evident in
the ITT analysis. Certainly the effectiveness of 63% under
unsupervised conditions in this study is unacceptably
low. This effectiveness might be higher with a fixed com-
bination better tasting syrup given under supervised con-
ditions.
Conclusion
The therapeutic life of this first line antimalarial recom-
mended for the treatment of uncomplicated P.falciparum
malaria [30,31] can be maintained. The effectiveness of
artesunate plus amodiaquine for treatment of falciparum
malaria in Lambaréné will depend on how well adherence
to this regimen can be ensured. The present plan of Drugs
for Neglected Diseases Initiative (DNDi) [32] and part-
ners to make this fixed-dose of artesunate-amodiaquine
available in 2006, calls for more effectiveness data on this
combination. This will guide policy implementation that
will assist malaria control programmes and clinics to
develop strategies that encourage adherence to this regi-
men, which in turn will prolong the effective life span of
this combination for the treatment of falciparum malaria
[20,33].
Table 1: Baseline characteristics
ATP population n Total 61 supervised 29 unsupervised 32 p-value
Number of participants (n) 61 29 32
Age (months) 61 15.1 (6.1) 14.0 (4.9) p = 0.3
Haemoglobin (g/dl) 53 8.7 (1.5) 8.1 (1.0) p = 0.2
Temperature (°C) 60 38.4 (1.2) 38.8 (1.2) p = 0.3
Neutrophils (k/μl) 48 2.8 (2.4) 3.1 (1.8) p = 0.6
Splenomegaly (n) 48 6.0 (12.5%) 10.0 (20.8%)
Data are mean (SD) or number (%).
Table 2: Day-28 cure rates
ATP population n total 61 supervised 29 unsupervised 32 p-value
Cure rate (PCR uncorrected) 44/61 (72%) 25/29 (86%) 19/32 (59%) 0.02
Cure rate (PCR corrected) 45/61 (74%) 25/29 (86%) 20/32 (63%) 0.04Malaria Journal 2007, 6:29 http://www.malariajournal.com/content/6/1/29
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